4D Molecular Therapeutics, Inc. (FDMT)
Nasdaq · Healthcare · Biotechnology
$12.92−5.49%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $714M
- 52-week range
- $6.96 – $16.93
- 52-week change
- +62.74%
- EPS (trailing)
- −$2.63
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 10, 2026
Fiscal year to Dec 2025
- Revenue
- $85.2M (+230194.59%)
- Net income
- −$140M
- Operating margin
- −187.2%
- Diluted EPS
- −$2.42
- Free cash flow
- −$110M
From the company’s annual report on SEC EDGAR.
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Headquarters: EmeryVille, United States · 196 employees · 4dmoleculartherapeutics.com